DOI: 10.4244/EIJ-D-17-00457L

Concerns about left atrial appendage occlusion

Claudia Stöllberger1*, MD; Birke Schneider2, MD

We read with great interest the article by Korsholm et al about transcatheter left atrial appendage occlusion (LAAO) in patients with atrial fibrillation (AF) and a high bleeding risk using aspirin (ASA) alone for post-implant antithrombotic therapy1. The authors conclude from their findings that LAAO with the AMPLATZER™ Cardiac Plug (ACP) or Amulet™ device (both St. Jude Medical, St. Paul, MN, USA) was safely performed with ASA monotherapy after implantation without an increased risk of device-related thrombosis or stroke. We have the following questions and concerns.

How do the authors explain the high mortality of the patients included in their study? Mortality is much higher than in other studies reporting on LAAO (Table 1) despite similar CHA2DS2-VASc scores2-4. It would be of great interest to know how long the estimated life expectancy was when the patients underwent LAAO.

Although the authors indicate that “none of the 20 deaths was procedure- or device-related”, it is important to know the exact cause of death. The left atrial appendage (LAA) is a structure for release of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP). In normal human hearts, ANP concentration is 40-fold higher in the LAA than in the rest of the atrial free wall and in the ventricular endocardium. Since natriuretic peptides play an important role in fluid regulation, volume homeostasis, and thirst perception, LAA elimination may impede physiologic regulation of heart failure and thirst perception. A decrease of ANP- and BNP-serum levels after LAAO has been described in small cohorts5,6. Furthermore, dysregulation of ANP and BNP has been associated with obesity, glucose intolerance, type 2 diabetes mellitus, and essential hypertension. Moreover, natriuretic peptides have been implicated in protection against atherosclerosis, thrombosis, and myocardial ischaemia7. Thus, some of these secondary effects might possibly explain the high mortality.

Although follow-up investigations by transoesophageal echocardiography and CT had been carried out in the majority of the study patients, astonishingly no information is given about the rate of leaks between the LAA wall and the devices. The LAA myocardium has a higher distensibility than the left atrial myocardium. Progressive dilation of the LAA is observed in AF and thereby leakage of an initially completely closed LAA may occur8. After surgical LAAO, leaks are associated with thromboembolic events9. Since it is unknown how many “late leaks” develop after interventional LAAO and whether they are clinically relevant, imaging studies later than 12 months post implantation should be implemented.

Conflict of interest statement

The authors have no conflicts of interest to declare.


References

Volume 13 Number 8
Oct 20, 2017
Volume 13 Number 8
View full issue


Key metrics

Suggested by Cory

10.4244/EIJ-D-17-00457R Oct 20, 2017
Left atrial appendage occlusion is promising, not concerning
free

Editorial

10.4244/EIJ-E-24-00001 Mar 4, 2024
Navigating the complexities of antithrombotic therapy after LAAO
Alkhouli M
free

10.4244/EIJV11I14A307 Apr 8, 2016
Percutaneous left atrial appendage occlusion in 2016
Tzikas A et al
free

10.4244/EIJV16I9A129 Oct 9, 2020
Left atrial appendage closure – ready for widespread clinical use?
Widimský P and Osmancik P
free

State-of-the-art

10.4244/EIJ-D-22-00627 Feb 6, 2023
Left atrial appendage occlusion
Holmes D et al
free

Editorial

10.4244/EIJ-E-24-00041 Aug 19, 2024
Left atrial appendage occlusion needs lifetime management not lifetime medications
Gafoor S and Panaich S
free
Trending articles
69.996

10.4244/EIJV13I12A217 Dec 8, 2017
Swimming against the tide: insights from the ORBITA trial
Al-Lamee R and Francis D
free
59.65

State-of-the-Art

10.4244/EIJ-D-24-00066 Apr 21, 2025
Management of complications after valvular interventions
Bansal A et al
free
57.6

State-of-the-Art

10.4244/EIJ-D-24-00386 Feb 3, 2025
Mechanical circulatory support for complex, high-risk percutaneous coronary intervention
Ferro E et al
free
38.75

State-of-the-Art

10.4244/EIJ-D-23-00912 Oct 7, 2024
Optical coherence tomography to guide percutaneous coronary intervention
Almajid F et al
free
15.85

State-of-the-Art

10.4244/EIJ-D-23-01050 Jul 15, 2024
Durability of transcatheter aortic valve implantation
Ternacle J et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved